Alterity Therapeutics Limited

NasdaqCM:ATHE 주식 보고서

시가총액: US$10.5m

Alterity Therapeutics 과거 수익 실적

과거 기준 확인 0/6

Alterity Therapeutics's earnings have been declining at an average annual rate of -2.6%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 9% per year.

주요 정보

-2.6%

수익 성장률

31.6%

EPS 성장률

Biotechs 산업 성장17.0%
매출 성장률9.0%
자기자본 수익률-138.6%
순이익-475.8%
최근 수익 업데이트30 Jun 2024

최근 과거 실적 업데이트

Recent updates

Alterity launches phase 2 study of ATH434 for multiple system atrophy in UK

Aug 25

Alterity begins dosing in mid-stage study of ATH434 for multiple system atrophy

Jul 06

Alterity: The Alternate Prana With New U.S. Patents In Iron Chaperone Technology

Sep 16

Alterity Therapeutics names Dr. David Stamler as CEO

Jan 07

Alterity and UniQuest partner to reverse bacterial resistance to antibiotics

Dec 21

Alterity Therapeutics nabs US patent for compounds for neurodegenerative disorders

Nov 16

수익 및 비용 분석

Alterity Therapeutics 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.


수익 및 매출 내역

NasdaqCM:ATHE 수익, 비용 및 수입 (AUD Millions )
날짜수익수익G+A 비용R&D 비용
30 Jun 244-19519
31 Mar 244-16515
31 Dec 233-12412
30 Sep 234-13512
30 Jun 234-14513
31 Mar 235-14514
31 Dec 225-14516
30 Sep 225-14515
30 Jun 225-13615
31 Mar 225-13514
31 Dec 215-13713
30 Sep 215-14813
30 Jun 214-15712
31 Mar 212-16711
31 Dec 200-16510
30 Sep 200-15410
30 Jun 200-13310
31 Mar 202-13411
31 Dec 194-13413
30 Sep 195-12413
30 Jun 195-12413
31 Mar 195-11412
31 Dec 184-10410
30 Sep 184-948
30 Jun 183-847
31 Mar 183-845
31 Dec 173-844
30 Sep 173-845
30 Jun 173-846
31 Mar 174-847
31 Dec 164-948
30 Sep 164-849
30 Jun 165-8410
31 Mar 165-8411
31 Dec 156-7512
30 Sep 156-7512
30 Jun 156-6512
31 Mar 158-6613
31 Dec 1410-7313
30 Sep 149-10314
30 Jun 148-13515
31 Mar 146-12313
31 Dec 134-11311

양질의 수익: ATHE is currently unprofitable.

이익 마진 증가: ATHE is currently unprofitable.


잉여현금흐름 대 수익 분석


과거 수익 성장 분석

수익추이: ATHE is unprofitable, and losses have increased over the past 5 years at a rate of 2.6% per year.

성장 가속화: Unable to compare ATHE's earnings growth over the past year to its 5-year average as it is currently unprofitable

수익 대 산업: ATHE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


자기자본 수익률

높은 ROE: ATHE has a negative Return on Equity (-138.6%), as it is currently unprofitable.


자산 수익률


고용 자본 수익률


과거 성과가 우수한 기업 찾기